Lophora

General Information

Company Name

Lophora

Founded Year

2018

Location (Offices)

Denmark +2

Founders / Decision Makers

Number of Employees

Industries

Biotechnology

Funding Stage

Convertible Note

Social Media

Lophora - Company Profile

Lophora is a Denmark-based biotechnology startup focused on developing next-generation psychedelic medicines to address various psychiatric disorders. Established in 2018, the company has made significant progress, including the successful completion of the initial characterization of its lead candidate LPH-5. This milestone was achieved through funding provided by the BioInnovation Institute (BII), the Novo Nordisk Foundation, public funds, and experienced biotech investors.

The efficacy of LPH-5 has been extensively characterized in vivo, and the drug has completed GLP-Tox, paving the way for the expected submission of a Clinical Trial Application (CTA) by Q2 2024. With a recent kr10.00M convertible note investment on 31st March 2020 from the BioInnovation Institute, Lophora is strategically positioned to initiate first-in-human trials by 2024. The company's commitment to addressing mental illness through innovative drug development makes it a compelling prospect for venture capital investment.

For more information, visit www.lophora.com.

Taxonomy: CNS drug discovery, psychedelic medicines, psychiatric disorders, clinical-stage, LPH-5, BII funding, biotech investors, first-in-human trials, GLP-Tox, CTA submission, mental illness, pharmaceutical research, psychopharmacology, neuroscience, clinical trials